Otsuka (OTCMKTS:OTSKY) Shares Gap Up – Here’s What Happened

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY – Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $32.94, but opened at $36.18. Otsuka shares last traded at $36.17, with a volume of 10,395 shares.

Analysts Set New Price Targets

Separately, Zacks Research raised Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Otsuka currently has a consensus rating of “Hold”.

Get Otsuka alerts:

View Our Latest Analysis on OTSKY

Otsuka Price Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67. The company has a 50 day moving average price of $34.44 and a 200 day moving average price of $32.70. The firm has a market cap of $38.96 billion and a PE ratio of 15.30.

Otsuka (OTCMKTS:OTSKY – Get Free Report) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.16. The firm had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.78 billion. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. Sell-side analysts expect that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 EPS for the current fiscal year.

About Otsuka

(Get Free Report)

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.

Read More

• Five stocks we like better than Otsuka
• 3 Dividend ETFs Built for Stability in a Volatile Market
• General Mills Is a 5-Star Turnaround Play for Buy and Hold Investors
• Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AI
• SMRs Spark a Chain Reaction for Nano Nuclear

Receive News & Ratings for Otsuka Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otsuka and related companies with MarketBeat.com's FREE daily email newsletter.